DAPA-TAVI: The #SGLT2 inhibitor dapagliflozin was superior to standard care alone in decreasing rates of all-cause mortality or worsening #HeartFailure in older adults w/ #vhdAS undergoing TAVI, resulting in a 28% relative risk ↘️. #ACC25

More: bit.ly/4cfLNsy

#cvSurg #CardioSky #MedSky